Grifols, a CataloniaBio & HealthTech member, concluded more than a year of encouraging results of its AMBAR (Alzheimer Management by Albumin Replacement) clinical trial with the presentation of new neuroimaging data that show the reduction in the progression of the disease in patients with mild-to-moderate Alzheimer’s disease.

These findings, released at the Clinical Trials on Alzheimer’s Disease Conference 2019 on 6 December in San Diego (USA), strengthen Grifols’ investigative approach using plasma protein replacement therapies.

More information

You may also be interested in:

• Grifols announces an investment plan of €1,400 million
• Grifols demonstrates a reduction of Alzheimer using its AMBAR treatment